- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Myriad Genetics Inc
Add to PortfolioMYGN:US
25.2000 USD 0.3300 1.29%As of 20:10:00 ET on 05/29/2012.
Snapshot for Myriad Genetics Inc (MYGN)
| Open: | 25.6400 | Day's Range: | 24.9765 - 25.7500 | Volume: | 1,021,353 | Bid: | 25.1900 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 25.5300 | 52wk Range: | 17.5100 - 27.0000 | 1-Yr Rtn: | -1.29% | Ask: | 25.2200 |
Key Statistics for MYGN
| Current P/E Ratio (ttm) | 20.0000 |
|---|---|
| Estimated P/E (06/2012) | 19.3846 |
| Earnings Per Share (USD) (ttm) | 1.2600 |
| Est. EPS (USD) (06/2012) | 1.3000 |
| Est. PEG Ratio | 1.7194 |
| Market Cap (M USD) | 2,138.62 |
| Shares Outstanding (M) | 84.87 |
| Enterprise Value (M USD) (ttm) | 1,671.91 |
| Enterprise Value/EBITDA (ttm) | 9.11 |
| Price/Book (mrq) | 3.2667 |
| Price/Sale (ttm) | 4.5540 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/09/2012 |
More MYGN Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for MYGN
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for MYGN
Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage.
| John T HendersonChairman | Walter GilbertVice Chairman/Co-Founder |
| Peter D MeldrumPresident/CEO/Co-Founder | James S EvansCFO/Treasurer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page